COMPOUND DEEP DIVES
SS-31 Elamipretide mitochondrial research has attracted considerable attention from the scientific community over the past two decades. The Szeto-Schiller peptide SS-31 — chemically designated D-Arg-2'6'-diMePhe-Lys-Phe-NH2 — is a tetrapeptide that researchers have observed selectively concentrating at the inner mitochondrial membrane (IMM), where it interacts with the phospholipid cardiolipin. Preclinical models indicate that this targeted binding may modulate electron transport chain (ETC) efficiency and attenuate reactive oxygen species (ROS) generation, positioning SS-31 as one of the most studied mitochondria-targeted compounds in contemporary research.
Cardiolipin is a tetra-acyl phospholipid found almost exclusively in the IMM, where it plays a structural and functional role in stabilising the respiratory supercomplexes — organised assemblies of Complexes I, III, and IV that maximise oxidative phosphorylation efficiency. In ageing cells and under ischaemic conditions, cardiolipin undergoes peroxidation, leading to the disorganisation of these supercomplexes and a consequent decline in ATP production.
Research led by Szeto HH and Birk AV and published across multiple peer-reviewed journals has demonstrated, in animal models, that SS-31 binds selectively to cardiolipin through electrostatic and hydrophobic interactions. This binding has been shown in preclinical models to:
Our team of specialist researchers has verified these mechanistic pathways across multiple independent in vitro and in vivo model systems, reinforcing the consistency of SS-31's cardiolipin-targeting profile in preclinical literature.
One of the most extensively studied preclinical applications of SS-31 involves cardiac ischaemia-reperfusion injury (IRI). When blood flow is restored to ischaemic myocardium, a burst of ROS production damages mitochondria and triggers cardiomyocyte death. Researchers have observed that pre-treatment with SS-31 in rodent IRI models significantly reduces infarct size relative to vehicle controls.
In a frequently cited study by Birk AV et al., isolated cardiac mitochondria exposed to simulated ischaemia-reperfusion conditions showed markedly improved respiration when incubated with SS-31 at nanomolar concentrations. Specifically, researchers recorded:
These findings in animal models suggest that cardiolipin-stabilising compounds like SS-31 may represent a mechanistically distinct approach to studying ischaemia-reperfusion biology at the mitochondrial level. Expert commentators in the field have noted that SS-31's ability to reach the IMM without requiring a mitochondrial membrane potential (unlike cationic lipophilic compounds such as MitoQ) is a notable pharmacokinetic differentiator observed across preclinical studies.
Beyond cardiac models, SS-31 Elamipretide mitochondrial research has expanded into chronic kidney disease (CKD) and ageing biology. In CKD mouse models, researchers have observed progressive mitochondrial fragmentation in renal tubular epithelial cells — a feature associated with impaired ATP production and heightened ROS output. Preclinical data from multiple groups indicate that SS-31 administration in these models is associated with:
In ageing research models, studies have documented an age-related decline in cardiolipin content and an accumulation of oxidised cardiolipin species in skeletal muscle and cardiac mitochondria. Animal model investigations comparing young versus aged subjects show that SS-31 administration is associated with partial reversal of age-associated ETC supercomplex disorganisation, as authenticated by blue-native polyacrylamide gel electrophoresis (BN-PAGE) analyses described in Szeto HH et al.
For researchers interested in complementary mitochondrial peptide targets, our authenticated reference library also covers Humanin mitochondrial peptide cytoprotection research and MOTS-c mitochondrial peptide metabolic research — both of which intersect with similar ETC and ROS biology explored in SS-31 preclinical literature.
To contextualise SS-31 within the broader landscape of mitochondria-targeted research compounds, the table below summarises key parameters reported across preclinical model literature. Note that direct head-to-head comparative studies are limited, and values reflect findings from independent model systems rather than a single controlled experiment.
| Parameter | SS-31 (Elamipretide) | Humanin | MOTS-c | MitoQ |
|---|---|---|---|---|
| Primary target | Cardiolipin / IMM | Bax / cytochrome c | AMPK / metabolic axis | Ubiquinone pool / IMM |
| Mitochondrial accumulation mechanism | Electrostatic (membrane-potential independent) | Receptor-mediated (FPRL1/CXCR4) | Cytoplasmic / nuclear translocation | Membrane potential-dependent (cationic) |
| ROS attenuation in animal models | Strongly observed (ETC stabilisation) | Observed (anti-apoptotic pathway) | Observed (AMPK-mediated antioxidant gene expression) | Strongly observed (direct scavenging) |
| ETC supercomplex stabilisation | Verified in multiple model systems | Limited direct evidence | Indirect (via metabolic reprogramming) | Not primary mechanism |
| Key preclinical model applications | Cardiac IRI, CKD, ageing skeletal muscle | Neurodegeneration, cardiac, metabolic | Metabolic disease, inflammation, ageing | Cardiac IRI, neurodegenerative, fatty liver |
| Cardiolipin interaction | Direct binding (primary mechanism) | Not established | Not established | Indirect (membrane localisation) |
This comparative framework is intended to assist researchers in contextualising SS-31's mechanistic profile relative to other compounds studied in mitochondrial biology. All data points are derived from peer-reviewed preclinical publications.
For laboratory investigators requiring authenticated, research-grade SS-31 Elamipretide, our specialist team supplies high-purity peptide preparations characterised by HPLC and mass spectrometry. All material is provided strictly for in vitro and in vivo preclinical research purposes in accordance with institutional guidelines.
View SS-31 Elamipretide for Research →
SS-31, also known as Elamipretide or MTP-131, is a synthetic tetrapeptide (D-Arg-2'6'-diMePhe-Lys-Phe-NH2) designed to selectively concentrate at the inner mitochondrial membrane. Researchers study it because preclinical models suggest it binds to cardiolipin and stabilises respiratory supercomplexes, potentially improving electron transport chain efficiency and reducing ROS generation under pathological conditions.
Research suggests that SS-31's alternating cationic and aromatic residues allow it to interact with cardiolipin's negatively charged phosphate head groups (electrostatic interaction) and its acyl chains (hydrophobic interaction). This dual interaction has been shown in animal models to inhibit the peroxidase activity of the cytochrome c/cardiolipin complex, thereby reducing lipid peroxidation at the IMM and preserving membrane architecture.
Researchers have employed a range of animal models including rat and mouse cardiac ischaemia-reperfusion injury models, adenine-induced CKD mouse models, aged rodent skeletal muscle preparations, and isolated mitochondria from various tissue types. Each model system has provided complementary mechanistic data on SS-31's cardiolipin-targeting properties and downstream ETC effects.
Both compounds target the inner mitochondrial membrane, but through distinct mechanisms. MitoQ is a cationic, lipophilic molecule that accumulates at the IMM driven by the mitochondrial membrane potential, where it functions primarily as a direct ROS scavenger via its ubiquinone moiety. SS-31, by contrast, accumulates at the IMM independently of membrane potential — through cardiolipin binding — and exerts its effects principally by stabilising respiratory supercomplexes rather than directly scavenging ROS. Researchers have observed this mechanistic distinction across multiple comparative in vitro studies.
Investigators have measured a range of bioenergetic parameters including State 3 (ADP-stimulated) and State 4 (oligomycin-inhibited) respiration rates, respiratory control ratio (RCR), Complex I, II, and IV enzymatic activities, ATP production rates, mitochondrial membrane potential (assessed by JC-1 or TMRM fluorescence), cytochrome c release, and supercomplex assembly by BN-PAGE. Preclinical data consistently show improvements across multiple parameters in SS-31-treated versus vehicle-treated mitochondria under stress conditions.
Yes, researchers have explored SS-31 extensively in the context of mitochondrial ageing. Preclinical models demonstrate an age-associated decline in cardiolipin content and accumulation of oxidised cardiolipin species, correlating with reduced ETC supercomplex stability and impaired ATP synthesis. Animal model studies have reported that SS-31 administration partially reverses these age-associated bioenergetic deficits in cardiac and skeletal muscle mitochondria, making it a compound of interest in longevity and mitochondrial ageing research programmes.
Our expert team supplies research-grade SS-31 Elamipretide verified by HPLC and mass spectrometry for use in approved preclinical laboratory settings. All material is accompanied by certificate of analysis documentation. Visit our SS-31 product page for full specifications. This compound is intended exclusively for scientific research and is not for human consumption.
This article is for informational and educational purposes only. All compounds discussed are intended strictly for laboratory and scientific research use. Not for human consumption. Not for sale to the public.